Perspectives for clinical use of engineered human host defense antimicrobial peptides.
Pachón-Ibáñez. María Eugenia ME; Smani. Younes Y; Pachón. Jerónimo J; Sánchez-Céspedes. Javier J
Key Findings
- Human host‑defense peptides (HDPs) have broad activity against Gram‑negative and Gram‑positive bacteria, viruses, and fungi.
- LL‑37 and its engineered derivatives also act as immune modulators, attracting immune cells and triggering cytokine release.
- Because HDPs work by non‑specific mechanisms, microbes are less likely to develop resistance, and they can neutralize toxins.
Practical Outcomes
- For biohackers, LL‑37 is an interesting candidate for future anti‑infection or immune‑boosting strategies, but it’s not yet a safe, tested supplement. Current research is still at the pre‑clinical or early clinical stage, so self‑administration is not recommended. Focus on proven lifestyle ways to support innate immunity while monitoring emerging LL‑37 studies for potential protocols.
Summary
The paper reviews human antimicrobial peptides like LL‑37, showing they can kill bacteria, viruses and fungi and also help the immune system without quickly causing resistance. It highlights ongoing work to turn these natural molecules into medicines, but it doesn’t give specific dosing or home‑use instructions.
Abstract
Infectious diseases caused by bacteria, viruses or fungi are among the leading causes of death worldwide. The emergence of drug-resistance mechanisms, especially among bacteria, threatens the efficacy of all current antimicrobial agents, some of them already ineffective. As a result, there is an urgent need for new antimicrobial drugs. Host defense antimicrobial peptides (HDPs) are natural occurring and well-conserved peptides of innate immunity, broadly active against Gram-negative and Gram-positive bacteria, viruses and fungi. They also are able to exert immunomodulatory and adjuvant functions by acting as chemotactic for immune cells, and inducing cytokines and chemokines secretion. Moreover, they show low propensity to elicit microbial adaptation, probably because of their non-specific mechanism of action, and are able to neutralize exotoxins and endotoxins. HDPs have the potential to be a great source of novel antimicrobial agents. The goal of this review is to provide an overview of the advances made in the development of human defensins as well as the cathelicidin LL-37 and their derivatives as antimicrobial agents against bacteria, viruses and fungi for clinical use.
Study Information
pubmed
2017
2017-05-01T00:00:00.000Z
10.1093/femsre/fux012
132
250